Authors
Latest:
Dr. Daskivich Discusses Active Surveillance in Prostate CancerTimothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses active surveillance for patients with prostate cancer.
Latest:
Dr. Whelan Provides a MA.20 Trial Result SummaryDr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary
Latest:
Dr. Kuzel on Immunotherapy as a Targeted Approach to CancerTimothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.
Latest:
Dr. Hughes on Switching From Imatinib to Nilotinib in CMLTimothy P. Hughes, MD, MBBS, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia.
Latest:
Dr. Pardee on CPI-613 for Patients With R/R AMLTimothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).
Latest:
Dr. Saettele on the Benefits of Using Bronchoscopies in NSCLCTimothy Saettele, MD, interventional pulmonologist at Saint Luke’s Hospital, discusses the benefits of using bronchoscopies in patients with non–small cell lung cancer (NSCLC).
Latest:
Practice Pearls for Community Oncologists Treating Early-Stage NSCLCA panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.
Latest:
Dr. Barbui on Hematocrit Levels in Polycythemia VeraTiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).
Latest:
Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCLToby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.
Latest:
Dr. Eyre on Resistance to BTK Inhibition in MCLToby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).
Latest:
Dr. Yezefski on Differences in CRC Care Costs Between the US and CanadaTodd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.
Latest:
Dr. Bauer on Evolution of Phase I TrialsTodd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses how phase I clinical trial programs are evolving and becoming more beneficial for patients with cancer.
Latest:
Therapy Class Review: Blood ModifiersIn reviewing the therapeutic category of blood modifiers, there are 3 areas of focus
Latest:
Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult ChoicesResults of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.
Latest:
Henricks Applies NASA Concepts to Medicine at Prostate CongressFormer NASA astronaut Tom Henricks will show how team dynamics and organizational culture affect outcomes using dramatic real-life video shot inside of a NASA space shuttle cockpit during launch and landing, as well as scenes of working in space, during a keynote address at the 8th Annual Interdisciplinary Prostate Cancer Congress (IPCC): and Other Genitourinary Malignancies.
Latest:
Expanding Cancer Screening: The Future of Blood-Based TestingClosing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Latest:
Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular CarcinomaTomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).
Latest:
Clinical Utility of Emerging Molecular Diagnostics in Breast CancerThe past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.
Latest:
Breast Cancer Chemoprevention: Targeting the Estrogen ReceptorNew strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.
Latest:
Dr Choueiri on Initial Efficacy Data With NKT2152 in Pretreated ccRCCToni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.
Latest:
Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCCToni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.
Latest:
Dr. Choueiri on Safety Profile of MK-6482 in Advanced Clear Cell RCCToni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.
Latest:
Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCCToni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.
Latest:
The Therapeutic Landscape of Metastatic Renal Cell Carcinoma in 2012In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.
Latest:
Anito-Cel Yields 100% Response Rate in R/R MyelomaAll patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.
Latest:
Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple MyelomaCilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.
Latest:
Biosimilars Gain Traction, Generate SavingsThe use of oncology biosimilars has expanded rapidly in the United States during the past 2 years as providers embraced a growing armamentarium of new products, according to findings from real-world data reported at the 2021 American Society of Clinical Oncology Annual Meeting.
